How do you identify the right endpoints For your CF trial?
Clinical trials in cystic fibrosis (CF) continue to investigate new therapies, including gene therapy, anti-inflammatory drugs and anti-infectives. This increases the challenge in identifying the right endpoints, including surrogate endpoints, to conclusively evaluate your compounds. As clinical trial patients are frequently children, getting accurate lung function data is challenging, adding to the study’s complexity.
ERT’s integrated solution ensures highest data quality and reduced variability.
Measure lung function efficacy endpoints like FEV1, lung clearance index (LCI) measurement, and DLCO along with cardiac safety endpoints, like centralized electrocardiograms (ECG) analysis, and imaging endpoints, like chest computer tomography (CT) and overread. Integration with eCOA enables patients to answer questionnaires for real-time insights into patient safety and study performance.
Experts in Respiratory Solutions
LEARN MORE ABOUT HOW ERT CAN SUPPORT YOUR CLINICAL TRIAL WITH AN INTEGRATED SOLUTION
Collects respiratory patient questionnaires for real-time insights into patient safety and study performance.
Captures, reads, and stores ECGs centrally to avoid the risk of false or inaccurate data.
Measures and analyzes imaging endpoints like chest computed tomography (CT) to provide on-demand evidence of drug safety and efficacy.